Engagement between HLA-G and killer-cell immunoglobulin-like receptor 2DL4 (KIR2DL4) desensitizes breast cancer cells to trastuzumab treatment or promotes metastasis by inducing matrix metalloproteinase (MMP)-9 expression (12, 13). Here, KIR2DL4 is linked to breast carcinoma.